Author:
Li Dan,Shi Yujian,Li Ang,Cao Dandan,Su Huijun,Yang Haiqi,Zhi Qihuan,Yang Yuchen,Lan Zhaoji,Zhou Tianliangwen,You Xiaobin,Hu Guifang
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference27 articles.
1. Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, et al. Report of cancer epidemiology in China, 2015. Zhonghua zhong liu za zhi [Chin J Oncology]. 2019;41:19–28.
2. Lipitor® China approved for first-line maintenance treatment of BRCA mutant advanced ovarian cancer [Internet] [cited 2020 Jan 15]. Available from: https://www.astrazeneca.com.cn/content/az-cn-zh/media/press-releases/2019/_-_brca_.html.
3. Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19:169–80.
4. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA J Am Med Assoc. 2012;307:382–90.
5. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol. 2015;33:1902–9.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献